HPB & Transplant Surgeon @NewcastleHosps UK | HPB & Transplant Surgery Fellow @nyulangone #NYC | MIS & robotic surgery | Pancreatic Research | Mountain goat
#ColorectalCancer liver metastasis detection timing—synchronous vs early or late metachronous—was not independently associated with overall survival after adjustment, supporting treatment planning guided by tumor burden and treatment feasibility.
https://t.co/y7txGPhx4F
HCC recurrence in liver transplants treated with hypothermic oxygenated machine perfusion: An international matched cohort study
@JHEP_Reports
https://t.co/z3SlLh1e6R
👉hypothermic oxygenated machine perfusion-treated liver transplant reduce risk of HCC reccurrence
🧐HOPE for HCC liver transplant
@myESMO@ASCO@EASLedu@ILCAnews
Postpancreatectomy-specific complications account for nearly half of in-hospital deaths after pancreatoduodenectomy. The long intervals between onset and mortality highlight opportunities to prevent failure to rescue. https://t.co/GvTRBkB7Gj
Our @MayoCancerCare Enterprise paper is finally out!
1,446 pts w “upfront resectable” PDAC.
Any vein abutment portended ⬇️OS, but this diff was mitigated when NAT was used.
⬆️aggressive vein resections didn’t change OS.
Time to redefine resectability?
https://t.co/7ay9d910lH
Patients with end-stage liver disease who had a potential living donor experienced a 26% reduction in waitlist dropout and 35% reduction in mortality risk from the time of listing. https://t.co/Yh3T4oLGn1
Yttrium-90 radioembolization is associated with a lower risk of liver transplant waitlist dropout than TACE in HCC
@JHepatology
https://t.co/GDIfBcfAf5
👉5677 LT candidates
👉more complete necrosis, lower likelihood of multiple LRTs & lower risk of waitlist dropout
@myESMO@EASLedu@ASCO@ILCAnews
“I’ve got kids who have the same genetic disease that I have and I certainly think about them all the time, and want them to have more options than my dad had, or my brother or I had.”
@nyulangone chair of surgery Dr. Bob Montgomery featured in @guardian:
https://t.co/W38EwzyAMb
✂️ How to determine resectability of locally advanced pancreas cancer?!
🎯 Suitable target is a disease-free arterial or venous segment above and below the tumor involvement
👷 “Reconstructability” is based on expertise and tumor biology 🧬
https://t.co/lxxWovImBN
@nyulangone@theliversurgeon Above all, I'm grateful for those two for enduring the journey with me and the sacrifices they make.. and looking forward to a new experience for the whole crew
Settling down in #NYC for my fellowship in HPB and liver transplant surgery at @nyulangone, all things complex livers and locally advanced pancreas surgery, complex robotic surgery and much more.
@nyulangone Grateful to Dr. Karim Halazun @theliversurgeon , Dr Christopher Wolfgang, Dr Robert Montgomery and the rest of an amazing team for the opportunity ! Looking forward to what the rest of the year brings
The human obsession with immortality or another life is fascinating...But then maybe the Pharaohs were onto something there .. They somehow continue to live and, they must feel vindicated
https://t.co/NXgrlAsW5R
Thank you 🙏
Definitely one of my pet peeves, people think giving a 40mmol of k in a bag of fluid will correct hypokalemia !!
The way I remember it: 200-400mmol of k to raise serm level by 1.0
AND
IV supp can't beat sandok if tolerated, unless in a big vein in ICU!
35 y , M, peri ampullary adenoca. jaundice and GOO +. For PD. On laparotomy, 1.7 cm liver lesion in S5, reported as hemangioma on preop scan. Frozen=malignant epithelial cells. How do you proceed? @IHPBA@hpb_so